118 related articles for article (PubMed ID: 16473668)
21. Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer.
Okegawa T; Nutahara K; Higashihara E
J Urol; 2008 Oct; 180(4):1342-7. PubMed ID: 18707699
[TBL] [Abstract][Full Text] [Related]
22. Gonadotropin-releasing hormone agonists reduce the migratory and the invasive behavior of androgen-independent prostate cancer cells by interfering with the activity of IGF-I.
Montagnani Marelli M; Moretti RM; Mai S; Procacci P; Limonta P
Int J Oncol; 2007 Jan; 30(1):261-71. PubMed ID: 17143537
[TBL] [Abstract][Full Text] [Related]
23. MicroRNA-21 directly targets MARCKS and promotes apoptosis resistance and invasion in prostate cancer cells.
Li T; Li D; Sha J; Sun P; Huang Y
Biochem Biophys Res Commun; 2009 Jun; 383(3):280-5. PubMed ID: 19302977
[TBL] [Abstract][Full Text] [Related]
24. Marked suppression of tumor growth by FTY720 in a rat liver tumor model: the significance of down-regulation of cell survival Akt pathway.
Ng KT; Man K; Ho JW; Sun CK; Lee TK; Zhao Y; Lo CM; Poon RT; Fan ST
Int J Oncol; 2007 Feb; 30(2):375-80. PubMed ID: 17203219
[TBL] [Abstract][Full Text] [Related]
25. Valproic acid inhibits invasiveness in bladder cancer but not in prostate cancer cells.
Chen CL; Sung J; Cohen M; Chowdhury WH; Sachs MD; Li Y; Lakshmanan Y; Yung BY; Lupold SE; Rodriguez R
J Pharmacol Exp Ther; 2006 Nov; 319(2):533-42. PubMed ID: 16868035
[TBL] [Abstract][Full Text] [Related]
26. Hormonal regulation of beta2-adrenergic receptor level in prostate cancer.
Ramberg H; Eide T; Krobert KA; Levy FO; Dizeyi N; Bjartell AS; Abrahamsson PA; Taskén KA
Prostate; 2008 Jul; 68(10):1133-42. PubMed ID: 18454446
[TBL] [Abstract][Full Text] [Related]
27. Novel mechanism of IGF-binding protein-3 action on prostate cancer cells: inhibition of proliferation, adhesion, and motility.
Massoner P; Colleselli D; Matscheski A; Pircher H; Geley S; Jansen Dürr P; Klocker H
Endocr Relat Cancer; 2009 Sep; 16(3):795-808. PubMed ID: 19509068
[TBL] [Abstract][Full Text] [Related]
28. Suppression of androgen receptor expression by dibenzoylmethane as a therapeutic objective in advanced prostate cancer.
Jackson KM; Frazier MC; Harris WB
Anticancer Res; 2007; 27(3B):1483-8. PubMed ID: 17595765
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of microtubule-active drugs followed by ketoconazole in human metastatic prostate cancer cell lines.
Blagosklonny MV; Dixon SC; Figg WD
J Urol; 2000 Mar; 163(3):1022-6. PubMed ID: 10688042
[TBL] [Abstract][Full Text] [Related]
30. Vasoactive intestinal peptide behaves as a pro-metastatic factor in human prostate cancer cells.
Fernández-Martínez AB; Bajo AM; Sánchez-Chapado M; Prieto JC; Carmena MJ
Prostate; 2009 May; 69(7):774-86. PubMed ID: 19189304
[TBL] [Abstract][Full Text] [Related]
31. Penta-O-galloyl-beta-D-glucose suppresses prostate cancer bone metastasis by transcriptionally repressing EGF-induced MMP-9 expression.
Kuo PT; Lin TP; Liu LC; Huang CH; Lin JK; Kao JY; Way TD
J Agric Food Chem; 2009 Apr; 57(8):3331-9. PubMed ID: 19320436
[TBL] [Abstract][Full Text] [Related]
32. Clioquinol, a therapeutic agent for Alzheimer's disease, has proteasome-inhibitory, androgen receptor-suppressing, apoptosis-inducing, and antitumor activities in human prostate cancer cells and xenografts.
Chen D; Cui QC; Yang H; Barrea RA; Sarkar FH; Sheng S; Yan B; Reddy GP; Dou QP
Cancer Res; 2007 Feb; 67(4):1636-44. PubMed ID: 17308104
[TBL] [Abstract][Full Text] [Related]
33. PC3, but not DU145, human prostate cancer cells retain the coregulators required for tumor suppressor ability of androgen receptor.
Litvinov IV; Antony L; Dalrymple SL; Becker R; Cheng L; Isaacs JT
Prostate; 2006 Sep; 66(12):1329-38. PubMed ID: 16835890
[TBL] [Abstract][Full Text] [Related]
34. Genistein inhibits matrix metalloproteinase type 2 activation and prostate cancer cell invasion by blocking the transforming growth factor beta-mediated activation of mitogen-activated protein kinase-activated protein kinase 2-27-kDa heat shock protein pathway.
Xu L; Bergan RC
Mol Pharmacol; 2006 Sep; 70(3):869-77. PubMed ID: 16772519
[TBL] [Abstract][Full Text] [Related]
35. PAR1-mediated RhoA activation facilitates CCL2-induced chemotaxis in PC-3 cells.
Loberg RD; Tantivejkul K; Craig M; Neeley CK; Pienta KJ
J Cell Biochem; 2007 Aug; 101(5):1292-300. PubMed ID: 17492768
[TBL] [Abstract][Full Text] [Related]
36. Protein kinase Cepsilon interacts with signal transducers and activators of transcription 3 (Stat3), phosphorylates Stat3Ser727, and regulates its constitutive activation in prostate cancer.
Aziz MH; Manoharan HT; Church DR; Dreckschmidt NE; Zhong W; Oberley TD; Wilding G; Verma AK
Cancer Res; 2007 Sep; 67(18):8828-38. PubMed ID: 17875724
[TBL] [Abstract][Full Text] [Related]
37. Signal transducer and activator of transcription-6 (STAT6) is a constitutively expressed survival factor in human prostate cancer.
Das S; Roth CP; Wasson LM; Vishwanatha JK
Prostate; 2007 Oct; 67(14):1550-64. PubMed ID: 17705178
[TBL] [Abstract][Full Text] [Related]
38. Human osteocalcin: a strong promoter for nitric oxide synthase gene therapy, with specificity for hormone refractory prostate cancer.
McCarthy HO; Coulter JA; Worthington J; Robson T; Hirst DG
J Gene Med; 2007 Jun; 9(6):511-20. PubMed ID: 17471586
[TBL] [Abstract][Full Text] [Related]
39. Expression of Nkx3.1 enhances 17beta-estradiol anti-tumor action in PC3 human prostate cancer cells.
Wang P; Liu B; Luo JD; Zhang ZG; Ma Q; Chen ZD
Asian J Androl; 2007 May; 9(3):353-60. PubMed ID: 17486276
[TBL] [Abstract][Full Text] [Related]
40. Selenite treatment inhibits LAPC-4 tumor growth and prostate-specific antigen secretion in a xenograft model of human prostate cancer.
Bhattacharyya RS; Husbeck B; Feldman D; Knox SJ
Int J Radiat Oncol Biol Phys; 2008 Nov; 72(3):935-40. PubMed ID: 18760546
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
